BackTitan Medical Overview

Titan Medical EBIT

Titan Medical's EBIT is $-21M, below the Healthcare sector average of $23B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$10.33M
20.72% YoY

As of Sep 30, 2022

Annual EBIT (TTM)

-$20.97M
53.29% YoY

Trailing 12 months ending Sep 30, 2022

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Titan Medical (TMDI) FAQ

The latest EBIT for TMDI is $-21M as of September 2022. That compares with $-45M in the prior-year period — up 53.3% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Titan Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, TMDI's EBIT moved from $-45M to $-21M — a 53.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Titan Medical's operating scale or balance-sheet position.

Against Healthcare companies, TMDI currently prints $-21M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Titan Medical's growth, margins, and balance sheet.

A EBIT figure of $-21M for TMDI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting TMDI's EBIT ($-21M), review year-over-year change from $-45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.